Pulmonx (LUNG) Narrative Resets Around Execution Risks and Fair Value Assumptions

Pulmonx's fair value estimate has been revised down from $5.75 to $5.17 per share, with analysts attributing the change to execution issues and a focus on core fundamentals. Canaccord maintained a positive stance despite the target reset, highlighting management's outlined actions to fix internal issues and refocus on fundamentals. The company's full-year 2026 revenue guidance of $90-$92 million provides a clear target for future updates.